MAIA Biotechnology, Inc., (NYSE American: MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced that an abstract ...

REHOVOT, Israel, March 28, 2025 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that seek ...

New non-clinical data strengthens evidence of contributions of IO102 and IO103 to tumor growth control through target specific T-cell activation, offering a distinct and complementary approach to ...

Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that seek to overcome tumor immune ...

REHOVOT, Israel, March 28, 2025 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech ... today announced upcoming poster presentations including one for CM24 in the treatment of pancreatic ...

Starton Therapeutics Inc. (“Starton” or the “Company”), a clinical-stage biotechnology company transforming standard-of-care therapies with proprietary dermal technologies, announced today that the ...

Novel trispecific T cell engager, ZW209, demonstrates potent preclinical efficacy against DLL3-expressing tumors and an ...

MAIA Biotechnology, Inc., (NYSE American ... a potential predictive biomarker for THIO treatment was selected for poster presentation at the European Lung Cancer Congress 2025 (ELCC 2025) taking ...

Less than 24 hours ago, u/ChipsNoDip shared a screenshot of DNA test results captioned: "Thought it'd be fun to get a test, ...

Oncolytics Biotech's main asset ... This was presented in a poster at ASCO GI 2025, showing that pelareorep treatment was feasible in the safety run-in. Nine patients were treated with the ...

Puma Biotechnology will present clinical data on its drug neratinib in a poster presentation on April 28 at the 2025 AACR Annual Meeting.